These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12807365)

  • 1. Assessing the economic impact of adverse drug effects.
    Rodríguez-Monguió R; Otero MJ; Rovira J
    Pharmacoeconomics; 2003; 21(9):623-50. PubMed ID: 12807365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic aspects of antibacterial adverse effects.
    Beringer PM; Wong-Beringer A; Rho JP
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):35-49. PubMed ID: 10175984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States.
    Rasu RS; Vouthy K; Crowl AN; Stegeman AE; Fikru B; Bawa WA; Knell ME
    J Manag Care Spec Pharm; 2014 Sep; 20(9):921-8. PubMed ID: 25166291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Impact of Emergency Visits due to Drug-Related Morbidity on a Brazilian Hospital.
    Freitas GRM; Tramontina MY; Balbinotto G; Hughes DA; Heineck I
    Value Health Reg Issues; 2017 Dec; 14():1-8. PubMed ID: 29254532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counting the costs of drug-related adverse events.
    White TJ; Arakelian A; Rho JP
    Pharmacoeconomics; 1999 May; 15(5):445-58. PubMed ID: 10537962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.
    Bloom BS
    Am J Med; 1988 Feb; 84(2A):20-4. PubMed ID: 3348239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulary management of antiulcer drugs: economic considerations.
    Tucker PP; Nash DB
    Pharmacoeconomics; 1994 Apr; 5(4):313-34. PubMed ID: 10147240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of preventable adverse drug reactions: a systematic review of observational studies.
    Formica D; Sultana J; Cutroneo PM; Lucchesi S; Angelica R; Crisafulli S; Ingrasciotta Y; Salvo F; Spina E; Trifirò G
    Expert Opin Drug Saf; 2018 Jul; 17(7):681-695. PubMed ID: 29952667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Related Morbidity in Brazil: A Cost-of-Illness Model.
    de Freitas GRM; Neyeloff JL; Balbinotto Neto G; Heineck I
    Value Health Reg Issues; 2018 Dec; 17():150-157. PubMed ID: 30195236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
    Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
    J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and length of stay of drug-related hospital admissions in cancer patients.
    Ko Y; Gwee YS; Huang YC; Chiang J; Chan A
    Clin Ther; 2014 Apr; 36(4):588-92. PubMed ID: 24636525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
    Chan SL; Ng HY; Sung C; Chan A; Winther MD; Brunham LR; Wee HL
    Pharmacogenomics J; 2019 Aug; 19(4):401-410. PubMed ID: 30250149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study.
    Patel KJ; Kedia MS; Bajpai D; Mehta SS; Kshirsagar NA; Gogtay NJ
    BMC Clin Pharmacol; 2007 Jul; 7():8. PubMed ID: 17662147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.
    Zabinski RA; Burke TA; Johnson J; Lavoie F; Fitzsimon C; Tretiak R; Chancellor JV
    Pharmacoeconomics; 2001; 19 Suppl 1():49-58. PubMed ID: 11280105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.
    Lanas A
    Aliment Pharmacol Ther; 2004 Aug; 20(3):321-31. PubMed ID: 15274669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients.
    Vermeulen KM; van Doormaal JE; Zaal RJ; Mol PG; Lenderink AW; Haaijer-Ruskamp FM; Kosterink JG; van den Bemt PM
    Int J Med Inform; 2014 Aug; 83(8):572-80. PubMed ID: 24929633
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.